Evidence map›Paper›PMID 27793964›Full record

ReviewCold Spring Harbor perspectives in medicine2017

The Whys and Wherefores of Antibiotic Resistance.

Cameron R Strachan, Julian Davies

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Mutations inMicrobiology spectrum · 2025
    Article
  3. Article
  4. Design, synthesis, and molecular docking studies ofJournal of Taibah University Medical Sciences · 2024
    Article
  5. Article
  6. Genome Sequence of Clinical Acinetobacter baumannii Strain V15.Microbiology resource announcements · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Antibiotics targeting bacterial ribosomal subunit biogenesis.The Journal of antimicrobial chemotherapy · 2020
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Cameron R StrachanMetaMixis Biologics, Vancouver, BC V6T 1Z3, Canada.
Julian DaviesDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development and rapid dissemination of antibiotic-resistant bacterial pathogens has tarnished the dream of a world without infectious diseases. However, our understanding of these processes, paired with sequence information from terrestrial bacterial populations, indicates that there is no shortage of novel natural products that could be developed into new medicines. Regardless, their therapeutic success in the clinic will depend on the introduction of mandatory controls and use restrictions.

Indexed as

AnimalsAnti-Bacterial AgentsBacteriaCommunicable DiseasesDrug Resistance, BacterialHumansAnti-Bacterial Agents

Identifiers

PMID27793964
PMCPMC5287056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.